Retatrutide Research Explained: What Phase 2 Trials Show

Why retatrutide keeps coming up

Retatrutide is an investigational weekly injection that activates three hormone receptors at once: GLP-1, GIP, and glucagon. That is why people call it a triple agonist. It is not the same as semaglutide (mainly GLP-1) or tirzepatide (GLP-1 plus GIP). Phase 2 trials in obesity and type 2 diabetes have reported large average weight changes and, in diabetes, meaningful HbA1c changes. Those findings are research results in study groups, not a promise for any one person.

If you already keep a GLP-1 tracker for a medication your provider prescribed, reading this research carefully helps you ask better questions at appointments. It does not tell anyone what to take. Only a licensed healthcare provider can judge whether any peptide or GLP-1 therapy fits your situation.

What a triple agonist is supposed to do

GLP-1 receptor agonists are already used widely for type 2 diabetes and chronic weight management under medical care. Adding GIP and glucagon receptor activity is an attempt to push appetite, metabolism, and glucose control further in one molecule. Retatrutide (also known as LY3437943 in study papers) was designed for that three-receptor profile.

How a person feels on any of these medicines still varies. Some people report strong appetite quieting. Others mainly notice gastrointestinal side effects early on. Study averages hide that spread, which is why personal logs of weight, side effects, and on-time doses matter when you review progress with a provider.

Phase 2 obesity trial: the headline numbers

In 2023, Jastreboff and colleagues published a phase 2, double-blind, randomized, placebo-controlled obesity trial in the New England Journal of Medicine (PubMed 37366315). Adults had a BMI of 30 or higher, or 27 to under 30 with at least one weight-related condition. They were assigned to several once-weekly retatrutide regimens or placebo for 48 weeks. The primary endpoint was percent weight change at 24 weeks.

Reported least-squares mean weight change at 24 weeks reached about -17.5% in the 12 mg group versus about -1.6% with placebo. At 48 weeks, the same 12 mg group averaged about -24.2% versus about -2.1% with placebo. Higher dose arms also had high shares of participants reaching 5%, 10%, and 15% weight-loss thresholds by week 48.

Gastrointestinal events were the most common adverse events, mostly mild to moderate, and more frequent at higher doses. The paper noted that beginning titration at a lower amount partly mitigated those events. Heart rate rose in a dose-related way, peaked around week 24, then declined. Those safety signals are exactly the kind of detail a provider watches when comparing options.

Phase 2 type 2 diabetes trial: glucose and weight

A separate phase 2 trial in people with type 2 diabetes, published in The Lancet, tested retatrutide against placebo and against dulaglutide 1.5 mg (PubMed 37385280). Adults had HbA1c between 7.0% and 10.5% and BMI between 25 and 50. Primary endpoint was HbA1c change at 24 weeks.

Higher retatrutide maintenance arms showed larger average HbA1c drops than placebo, and some arms beat dulaglutide on that measure. Body weight also fell in a dose-related pattern by 36 weeks, with higher arms reporting average reductions in the mid-teens percent range, far above the small changes seen with placebo or dulaglutide in that study. Mild to moderate GI events again showed up often, especially with faster escalation.

Taken together, the obesity and diabetes phase 2 programs paint a consistent picture: strong average weight effects, useful glucose effects in diabetes, and a side-effect profile that looks a lot like other incretin therapies. Phase 3 programs are meant to confirm that picture in larger groups. Until regulators finish that path, retatrutide remains investigational for clinical use outside trials.

How retatrutide sits next to semaglutide and tirzepatide

Readers who already track semaglutide or tirzepatide often want a simple comparison. Semaglutide is a GLP-1 receptor agonist. Tirzepatide hits GLP-1 and GIP. Retatrutide adds glucagon. Cross-trial comparisons are imperfect because populations, lifestyle support, and follow-up differ. Still, the phase 2 obesity averages for the highest retatrutide arm sit in a range that many clinicians describe as among the largest reported for a weekly injectable in that setting.

That does not mean "more receptors always equal better for you." Glucagon activity may change energy use and heart rate in ways dual agonists do not. Individual risk, other medicines, and goals belong in a provider conversation, not in a blog post.

For background on how approved GLP-1 medicines are described for patients, MedlinePlus has a clear overview of semaglutide as one example of the class. Always treat package labeling and your clinician as the source of truth for any medicine you are actually prescribed.

What is useful to track if you follow this research

Even if you are only reading about retatrutide while staying on a different GLP-1 your provider already chose, the trial endpoints point to a practical tracking list:

1. Weight on a consistent schedule (same scale, similar time of day), logged next to doses.
2. On-time versus missed doses, because adherence shapes real-world results more than people admit.
3. Side-effect check-ins with a simple severity scale, especially nausea, vomiting, diarrhea, and constipation during any titration window your provider set.
4. Heart-rate notes if your clinician asked you to watch them.
5. Appointment packet: a short printout or export of dose history and weight trend for the visit.

A dedicated weight tracking view next to dose history makes those trends easier to spot than a notes app. Dose reminders help the on-time percentage stay honest. None of those tools replace clinical judgment. They just keep the raw record clean.

If your protocol uses reconstituted vials rather than a branded pen, write down vial strength, water added, and the dose your provider gave you. Peppy's free peptide calculator turns those three numbers into syringe units for record-keeping. It does not recommend a dose. Swap any placeholder for exactly what your provider wrote.

Keeping a GLP-1 log in Peppy

Peppy is a peptide tracker app for iPhone that many people also use as a GLP-1 tracker. You enter the dose your provider gave you, log each shot, rotate injection sites, and keep weight and side-effect notes on your phone. Your data stays on the device and in your own iCloud backup, which makes it easy to bring a clear record to your next appointment.

Practical takeaways

Retatrutide phase 2 data are striking on average weight and, in diabetes, on HbA1c. GI side effects and a temporary heart-rate rise are part of the published safety story. The molecule is still moving through larger trials. If you are on any GLP-1 or related therapy under a provider's care, use a clear log so appointments stay grounded in your numbers, not memory. Read the primary papers when you can, bring questions, and let your clinician decide what the research means for you.